2018 Short Bowel Syndrome Drug Development- Pipeline Analysis Report

May 2018 | | ID: 22E90685F37EN
VPAResearch

Abstracts

Short Bowel Syndrome is a rare gastrointestinal disease with a prevalance rate of 4 per million. It is typically categorized into three stages- acute, adaptive and maintenance. The condition occurs following extensive intestinal resection.

Over 15 companies and universities are focusing on developing treatment options for Short Bowel Syndrome.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Short Bowel Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Short Bowel Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Short Bowel Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 SHORT BOWEL SYNDROME PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Short Bowel Syndrome Pipeline Snapshot
2.3 Short Bowel Syndrome Pipeline by Phase
2.4 Short Bowel Syndrome Pipeline by Company
2.5 Short Bowel Syndrome Pipeline by Mechanism of Action

3 SHORT BOWEL SYNDROME- COMPANY WISE PIPELINE ANALYSIS

Genexine
Hanmi Pharmaceuticals
Naia Ltd
Naia Ltd
Napo Pharmaceuticals
Nutrinia Ltd
OxThera AB
Sancilio & Company Inc
Shire Plc
Zealand Pharma AS

4 SHORT BOWEL SYNDROME R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN SHORT BOWEL SYNDROME PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Short Bowel Syndrome Pipeline by Phase, H1- 2018
Figure 2: Short Bowel Syndrome Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Short Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Short Bowel Syndrome Pipeline by Phase, H1- 2018
Table 2: Short Bowel Syndrome Pipeline by Companies, H1- 2018
Table 3: Short Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018
Table 4: Genexine Short Bowel Syndrome pipeline, May 2018
Table 5: Hanmi Pharmaceuticals Short Bowel Syndrome pipeline, May 2018
Table 6: Naia Ltd Short Bowel Syndrome pipeline, May 2018
Table 7: Naia Ltd Short Bowel Syndrome pipeline, May 2018
Table 8: Napo Pharmaceuticals Short Bowel Syndrome pipeline, May 2018
Table 9: Nutrinia Ltd Short Bowel Syndrome pipeline, May 2018
Table 10: OxThera AB Short Bowel Syndrome pipeline, May 2018
Table 11: Sancilio & Company Inc Short Bowel Syndrome pipeline, May 2018
Table 12: Shire Plc Short Bowel Syndrome pipeline, May 2018
Table 13: Zealand Pharma AS Short Bowel Syndrome pipeline, May 2018